Barclay “Buck” Phillips

Barclay “Buck” Phillips brings over 35 years of life science investing, company creation, financial reporting, financing strategy, operations, and business development experience to Immunic.

From 2008 to 2024, Mr. Phillips served as the Chief Financial Officer, Chief Operating Officer, and/or Senior Vice President of Business Development for four separate, discovery and development stage biotechnology companies (Ribometrix, Inc. (Private), G1 Therapeutics, Inc. (NASDAQ, GTHX), Novavax, Inc. (NASDAQ, NVAX) and Micromet, Inc. (acquired by Amgen in 2012 for $1.2B)). In these roles, Mr. Phillips was responsible for all finance and accounting functions, financing strategy (successfully raising over $1.4 billion), Wall Street and investor relations, and public relations. In addition to his finance responsibilities, in several of these roles, he was responsible for operations, corporate strategy, business development and corporate development.

Prior to his role on the operating side of the business, Mr. Phillips developed extensive experience in life science venture investing, having spent 9 years as a Managing Director of Vector Fund Management, a late-stage life sciences venture capital fund with over $250 million in committed capital and approximately 30 venture investments in biotechnology, medical technology and healthcare services companies. In addition, Mr. Phillips spent eight years as a Biotechnology Analyst and Director of Venture Investments for INVESCO Funds group, a no-load mutual fund family with a healthcare sector fund franchise totaling over $3.5 billion in assets under management.

Mr. Phillips has served on the board of several public and private companies, including roles as Audit Chair, Chair of the Nominating and Corporate Governance committees, and Compensation committees. He received a Bachelor of Arts degree in economics from the University of Colorado at Boulder.

Mr. Phillips has been a member of Immunic’s Board since November 2019. He is chairman of the Audit Committee and a member of the Nominating and Corporate Governance Committee.